Most Read Articles
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 5 days ago
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, Yesterday

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.

Respiratory diseases linked to RA risk among nonsmokers

12 Sep 2020

Patients with respiratory diseases risk developing seropositive or seronegative rheumatoid arthritis (RA), although this association is limited only to nonsmokers, a study has found.

Researchers used data from the Epidemiological Investigation of Rheumatoid Arthritis study and identified 1,631 incident RA patients (median age at enrolment, 57 years; 71 percent female) and 3,283 matched controls.

In the RA group, 1,088 of 1,573 patients (69 percent) were positive for anticitrullinated peptide antibody (ACPA) while 1,059 of 1,615 (66 percent) were positive for rheumatoid factor (RF). As expected, smoking was strongly associated with RA risk, especially ACPA-positive RA.

In multivariable logistic regression models, respiratory disease diagnoses were associated with an increased risk of RA. Specifically, acute upper respiratory disease conferred a 20-percent risk increase (adjusted odds ratio [aOR], 1.2, 95 percent confidence interval [CI], 0.8–1.7), chronic upper diseases a 40-percent increase (aOR, 1.4, 95 percent CI, 1.1–1.9), acute lower diseases a 140-percent increase (aOR, 2.4, 95 percent CI, 1.5–3.6), and chronic lower diseases a 60-percent increase (aOR, 1.6, 95 percent CI 1.2–2.3).

The associations were independent of RF or ACPA status, although somewhat stronger for RA patients positive vs negative for ACPA/RF. Furthermore, the risk increase associated with any respiratory disease and RA was more pronounced for nonsmokers (aOR, 2.1, 95 percent CI, 1.5–2.9) than smokers (aOR, 1.2, 95 percent CI, 0.9–1.5).

The findings raise the hypothesis that smoking and airway disease are associated with RA development through partly different mechanisms, which suggest that taking precautions to prevent respiratory diseases may be just as important as smoking cessation in individuals at risk of RA, according to the researchers. They pointed out that stratifying by smoking status may reveal additional risk factors and pathogenic mechanisms underlying RA, which would otherwise be masked.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 5 days ago
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, Yesterday

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.